5-Phenyl-2,4-pentadienoic acid Clinical Trials

Size	Price	Qty
25mg	USD 97

Clinical Trials

Multiple clinical trials are currently investigating infectious, cardiovascular, and oncological indications, focusing on Chlamydia trachomatis infection, Neisseria gonorrhoeae infection, asymptomatic conditions, coronary heart disease in coronary artery bypass grafting patients, and breast cancer. Spanning Phase 1, Phase 2, and non-applicable phase evaluations, these studies are sponsored by industrial entities such as Abbott Rapid Dx and Novartis Pharmaceuticals alongside academic institutions like the University of California, Los Angeles. Currently listed with a recruitment status of not yet recruiting, these records capture an early-stage clinical evaluation landscape across diverse therapeutic areas.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06395675	Not yet recruiting	Chlamydia Trachomatis Infection\|Neisseria Gonorrheae Infection\|Asymptomatic Condition	Abbott Rapid Dx	2024-07-09	Not Applicable
NCT06326996	Not yet recruiting	Coronary Heart Disease\|Coronary Artery Bypass Grafting	University of California Los Angeles	2024-05	Not Applicable
NCT06247995	Not yet recruiting	Breast Cancer	Novartis Pharmaceuticals\|Novartis	2024-05-16	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 5-Phenyl-2,4-pentadienoic acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

5-Phenyl-2,4-pentadienoic acid acts by binding to key target enzymes involved in critical metabolic pathways, thereby blocking downstream biochemical reactions and disrupting essential cellular activities. This inhibition leads to impaired cellular viability and growth, providing a mechanistic rationale relevant to clinical trial conditions such as breast cancer and infectious diseases.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).